Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 mg daily dose compared to placebo. read more
Read Also
- Postmedia board member to step down to pursue political career
- Samsung is offering $1,000 off one of its best OLED TVs, and shoppers say it is 'out of this world'
- Walmart is selling a 'space-saving' $200 cookware set for only $55, but not for long
- Salesforce CEO Says the Company's New AI Agents Could Replace Human Jobs
- Congratulations! You’re (Maybe) Getting a 4% Raise Next Year
- Acquiring a Business? You Need to Assemble a Team With These 5 Roles to Make It a Success.
- Midday stock movers: FedEx, Constellation Energy, Nike
- Midday stock movers: FedEx, Constellation Energy, Nike
- How Businesses Can Succeed in Overcoming the Language Barrier in Multilingual Markets
- Carnival Cruise Line adds an item to banned list
Latest Benzinga
- Why Is Agilent Up 1.2% Since Last Earnings Report?
- Chevron Unusual Options Activity For September 20
- Chevron Unusual Options Activity For September 20
- Spotlight on Roblox: Analyzing the Surge in Options Activity
- Spotlight on Roblox: Analyzing the Surge in Options Activity
- 9 Communication Services Stocks With Whale Alerts In Today's Session
- 9 Communication Services Stocks With Whale Alerts In Today's Session
- 10 Financials Stocks With Whale Alerts In Today's Session
- 10 Information Technology Stocks Whale Activity In Today's Session
- 10 Information Technology Stocks Whale Activity In Today's Session